MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Revenue 2011-2026 | ARDS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.09 M | 1.54 M | 1 K | 1.02 M | 2.76 M | 860 K | 2.27 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 M | 1 K | 1.65 M |
Quarterly Revenue Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 417 K | - | 399 K | 292 K | 1.19 M | - | 515 K | 33 K | - | - | 1 M | 1 M | -9 K | - | 1.02 M | 1.02 M | 1.02 M | - | 1.02 M | 22 K | 322 K | - | 22 K | 22 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 M | -9 K | 548 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
21 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
502 M | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
300 K | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
477 K | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
451 M | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Beam Therapeutics
BEAM
|
140 M | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
9.89 B | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.9 M | $ 2.91 | 2.83 % | $ 908 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
48.2 B | $ 62.54 | 0.27 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
75 K | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 109.85 | -0.34 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
2.27 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.6 | 1.9 % | $ 1.39 B | Britain |